Previous 10 | Next 10 |
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will ...
Savara (NASDAQ:SVRA): Q3 GAAP EPS of -$0.07 beats by $0.02. Revenue of $0M Press Release As of September 30, 2021, Savara had cash, cash equivalents, and short-term investments of approximately $171 million and debt of approximately $25 million. For further details see: Savara EPS beats...
Continued to Advance Pivotal Phase 3 IMPALA 2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP); 20-Month Enrollment Guidance Remains On-Track Received Acceptance from Pediatric Committee of the European Medicines...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021. A pre-recorded, on-demand webcast of ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT. ...
H.C. Wainwright 23rd Annual Global Investment Conference Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its managemen...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On September 2, 2021, the Compensation Committee of Savara’s Board of Directors granted induce...
Advancing Pivotal Phase 3 IMPALA 2 Trial of Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP); Numerous Clinical Trial Sites Activated, Patients Dosed, Timelines Remain on Track Cash Balance of ~$181M; Company Believes it is Sufficiently...
Savara ([[SVRA]] +0.6%) announces that the first patient has been dosed in the company's late-stage trial testing its drug molgramostim in patients with autoimmune pulmonary alveolar proteinosis ((aPAP)), a rare lung disease.The trial is a 48-week, randomized, double-blind, placebo-...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...